John Sullivan is an Ophthalmology physician. ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7740 Point Meadows Dr
Suite 3a
Jacksonville, FL 322569179
Telephone
904-527-3577Registry record last updated 5 Apr 2017.
Clinical trials
- A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Sponsor: Western Sydney Local Health District
- Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
Sponsor: ContraVir Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20253 payments
- Regeneron Healthcare Solutions, Inc.Program year20253 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
79.9%Antineovascularisation agents38.6%Faricimab-svoa100%Part B, office-administered≥33 patientsComplement Inhibitor10.3%Avacincaptad pegol100%Part B, office-administered≥27 patients+ 10 more classes in this area
Cancer & immunology
17.6%Vascular Endothelial Growth Factor Inhibitor17.6%Aflibercept75%Bevacizumab23%Eylea3%Part D + Part B≥200 patientsDermatology
0.7%Corticosteroid0.7%Triamcinolone acetonide100%Part B, office-administered≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”